Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lopinavir/ ritonavir · 1 trial · 2 indications
Proportion of participants with a negative high-risk human papillomavirus (hrHPV) qualitative test at 3 months post end of treatment
| Arm | Type | Description |
|---|---|---|
| DARE-HPV-LD 14 day | ACTIVE_COMPARATOR | 14 day administration of DARE-HPV low dose |
| DARE-HPV-LD 21 day | ACTIVE_COMPARATOR | 21 day administration of DARE-HPV low dose |
| DARE-HPV-HD 14 day | ACTIVE_COMPARATOR | 14 day administration of DARE-HPV high dose |
| DARE-HPV-HD 21 day | ACTIVE_COMPARATOR | 21 day administration of DARE-HPV high dose |
| Placebo 14 day | NO_INTERVENTION | 14 day administration of placebo product |
| Placebo 21 day | NO_INTERVENTION | 21 day administration of placebo product |
| Name | Type | Description |
|---|---|---|
| Lopinavir / ritonavir | DRUG | A fixed-dose ration combination (12:1) of lopinavir and ritonavir in a vaginal capsule. |
Inclusion Criteria: 1. Provision of written informed consent prior to any study-specific procedures. 2. Premenopausal women aged 22-50 years inclusive at the time of screening visit. 3. Positive result for genital hrHPV (types 16, 18, or 'other') on at least 2 tests over the span of at least 12 mon...
Lopinavir/ritonavir is being studied for the treatment of high-risk persistent Human Papilloma Virus (HPV) infection. It is an investigational small molecule combination therapy in Phase 2 clinical development for this indication.
Lopinavir/ritonavir is a combination of two protease inhibitors that work by inhibiting the viral protease enzyme, which is essential for viral replication. This mechanism is being evaluated for its potential to treat high-risk persistent HPV infection.
Lopinavir/ritonavir is being developed by Dare Bioscience, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DARE. The company is conducting clinical trials to evaluate the drug for HPV treatment.
Lopinavir/ritonavir is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the treatment of HPV. The ongoing Phase 2 trial is designed to assess its preliminary efficacy.
Lopinavir/ritonavir is being evaluated in a Phase 2 clinical trial with the identifier NCT07601074. This randomized, double-blind, active-controlled study is investigating the preliminary efficacy of DARE-HPV in treating high-risk persistent HPV infection in women aged 22 years and older in the United States.
Yes, Lopinavir/ritonavir is the same as Lopinavir / ritonavir. The two names refer to the identical drug combination being developed by Dare Bioscience, Inc. for the treatment of high-risk persistent HPV infection.